The tweet was deleted by the author.
But we saved everything 🙂.
Lexicon Pharmaceuticals is intensifying efforts to expand treatment options for chronic pain, including diabetic peripheral neuropathic pain (DPNP), spotlighting the need for greater industry and public focus on this area.
The company promoted Dr. Webster’s recent article on novel approaches to chronic pain and highlighted his participation in Lexicon Pharmaceuticals' Chronic Pain Roundtable, where non-opioid innovations were central to the discussion. The push for broader solutions comes amid ongoing scrutiny of opioid use, signaling potential new directions for pharmaceutical interventions in pain management.
Lexicon’s commitment to broadening therapeutic avenues for chronic pain builds on its established efforts to address diverse unmet medical needs. The company has previously outlined strategies for leveraging ACSL5 as a potential obesity treatment target, underscoring its focus on innovative biological pathways. Additionally, its push to introduce new treatments in the hypertrophic cardiomyopathy community further highlights Lexicon’s multifaceted approach to advancing patient care across a range of challenging conditions.